Table 6.
Rank order correlations for the combined in vitro (cell lines) and in vivo (BALB/c mouse) particle potency estimates for all particles (PM) and excluding cristobalite (CRI)
| Particle potency estimates | Particles | Ranking in vitro | Ranking in vivo | Rank-order correl. (All PM)a | Rank-order correl. (no CRI)b | ||||
|---|---|---|---|---|---|---|---|---|---|
| R | p (1-tailed) | R | p (1-tailed) | ||||||
| Toxicity βR CELLS vs. βT BALB/c |
CRI | 5 | - | 3 | - | ||||
| DWR1 | 4 | (4) | 5 | (4) | |||||
| EHC-2000 | 2 | (2) | 2 | (2) | 0.667 | 0.109 | 1.000 | <0.001 | |
| SRM-1649 | 1 | (1) | 1 | (1) | |||||
| TiO2 | 3 | (3) | 4 | (3) | |||||
| Inflammation βI-V CELLS vs. βI BALB/c |
CRI | 4 | - | 3 | - | ||||
| DWR1 | 5 | (4) | 5 | (4) | |||||
| EHC-2000 | 1 | (1) | 2 | (2) | 0.800 | 0.052 | 0.800 | 0.100 | |
| SRM-1649 | 2 | (2) | 1 | (1) | |||||
| TiO2 | 3 | (3) | 4 | (3) | |||||
| Integrated Potency Iβ CELLS vs. Iβ BALB/c |
CRI | 4 | - | 3 | - | ||||
| DWR1 | 5 | (4) | 5 | (4) | |||||
| EHC-2000 | 1 | (1) | 2 | (2) | 0.800 | 0.052 | 0.800 | 0.100 | |
| SRM-1649 | 2 | (2) | 1 | (1) | |||||
| TiO2 | 3 | (3) | 4 | (3) | |||||
Particle ranking based on integrated particle potency estimates across cell types and in vitro or in vivo endpoints, where the lowest number represents the most potent particle
The ranking outside brackets includes all PM, the ranking within brackets excludes CRI
aSpearman’s rank-order correlation and p-values (1-tailed) on ranked corresponding in vitro and in vivo potency estimates for all PM, bexcluding CRI
Numbers in bold represent statistically significant correlations (p ≤ 0.05)